
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence
Nov 24, 2025 09:43 am UTC| Business Health
Bayers experimental stroke treatment, asundexian, delivered strong results in the Phase III OCEANIC-STROKE trial, prompting renewed optimism for the pharmaceutical giant. Analysts, including Goldman Sachs James Quigley,...

Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Nov 22, 2025 03:47 am UTC| Business Health
Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach this milestone. The companys extraordinary rise is fueled largely by explosive global demand for...

Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Nov 14, 2025 02:01 am UTC| Business Health
Merck is reportedly close to finalizing a deal to acquire Cidara Therapeutics, offering a premium over the biotechnology companys current market value of about $3.3 billion. According to a report from the Financial Times,...

Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Nov 11, 2025 01:00 am UTC| Health Governance
Canada has lost its measles elimination status after nearly three decades, following a year-long outbreak that the Pan American Health Organization (PAHO) confirmed on Monday. The setback also affects the Americas region,...

Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Nov 10, 2025 13:44 pm UTC| Business Health Science
Cogent Biosciences (NASDAQ: COGT) shares skyrocketed over 120% after the biotech company announced groundbreaking results from its Phase 3 PEAK trial evaluating bezuclastinib in combination with sunitinib for patients with...

Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Nov 09, 2025 00:37 am UTC| Business Health
Pfizer has sealed a $10 billion acquisition of obesity drug developer Metsera, marking a major victory in the rapidly expanding weight-loss drug market. The New York-based pharmaceutical giant outbid Danish rival Novo...

Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Nov 08, 2025 01:48 am UTC| Business Health
Pfizer Inc. has reportedly increased its takeover offer for Metsera, a U.S.-based obesity drug developer, signaling its determination to outpace Danish rival Novo Nordisk in the lucrative weight-loss treatment market....